Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

PURPOSE: Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities. PATIENTS AND METHODS: We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically sun-damaged (CSD) melanoma with KIT amplifications and/o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Hodi, F. Stephen, Corless, Christopher L., Giobbie-Hurder, Anita, Fletcher, Jonathan A., Zhu, Meijun, Marino-Enriquez, Adrian, Friedlander, Philip, Gonzalez, Rene, Weber, Jeffrey S., Gajewski, Thomas F., O'Day, Steven J., Kim, Kevin B., Lawrence, Donald, Flaherty, Keith T., Luke, Jason J., Collichio, Frances A., Ernstoff, Marc S., Heinrich, Michael C., Beadling, Carol, Zukotynski, Katherine A., Yap, Jeffrey T., Van den Abbeele, Annick D., Demetri, George D., Fisher, David E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2013
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878082/
https://ncbi.nlm.nih.gov/pubmed/23775962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.7836
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares